Philip Morris’ comeback act is bold, targeted, and might just work

Few industries have faced as much long-term pressure as tobacco. For years, the global anti-smoking push threatened to hollow out legacy giants like Philip Morris International.

But the Marlboro maker is staging a high-stakes pivot toward smoke-free alternatives, and the market seems to be rewarding the gamble so far.

PM shares have more than doubled over the past five years, with 2026 starting off with additional gains. So is this slow-motion turnaround still in its early stages or has most of the upside already been priced in?

Unwrapping the bold strategy

This corporate reinvention has been decades in the making, but management’s latest update shows the transition is accelerating.

Here’s where things stand right now:

• A goal of earning more than 66% of all revenue from smoke-free products by 2030
• Currently, about 41.5% of revenue is already coming from smoke-free sources
• Smoke-free products generate 2.5x more revenue per unit than cigarettes
• Organic revenue growth target is in the 6%-8% range through 2028
• Adjusted EPS growth target comes in between 9% and 11%.

And the momentum is still moving in the right direction. Smoke-free volume grew 12.8% last year, while smoke-free gross profit jumped 18.7%. Flagship products like IQOS and ZYN continue expanding across global markets.

Wall Street generally views the pivot as credible, but it’s a delicate balancing act. Philip Morris International must grow new categories fast enough to offset the steady decline in traditional cigarettes.

Where the road leads from here

Analyst sentiment remains constructive, but the outlook stops short of euphoria.

PM stock maintains a consensus rating of moderate buy with an average target of about $194, up slightly from yesterday’s $187 close. Institutional ownership is hovering in the upper-70% range with dividend yield of roughly 3.2%.

Citi recently raised its price target to $210 with a buy rating, but institutional positioning is mixed. For example, Trajan Wealth boosted its stake by 31% while Hillsdale trimmed its position by almost the same percentage.

Valuation is the primary sticking point. PM trades near 25x earnings, and some fair-value models suggest only mid-single-digit annual returns from here.

Bottom line? Philip Morris has executed one of the market’s more impressive reinventions, but investors might have already cashed in on all the easy money.

Looking ahead, institutions are treating PM stock as a steady compounder while watching for signs that smoke-free growth is more than offsetting the continued cigarette decline.